Iterum Therapeutics plc 8-K

What Happened
Iterum Therapeutics plc announced that Nasdaq has determined to delist its ordinary shares after the company withdrew its appeal of a prior delisting determination for failing to maintain a $1.00 minimum bid price. The company filed a Winding Up Petition in the High Court in Ireland on March 27, 2026, and joint provisional liquidators from Teneo Restructuring (Ireland) Limited—Damien Murran and Jennifer McMahon—are overseeing the winding‑up process. Nasdaq notified Iterum on March 30, 2026 that trading will be suspended at the opening of business on April 1, 2026 and a Form 25‑NSE will be filed to remove the shares from Nasdaq.

Key Details

• Nasdaq issued the original delisting determination on February 24, 2026; Iterum requested a hearing on March 3, 2026 but later withdrew the appeal.
• Winding Up Petition filed in the High Court in Ireland on March 27, 2026; joint provisional liquidators are Damien Murran and Jennifer McMahon of Teneo Restructuring (Ireland) Limited.
• Trading suspension effective at the opening of business April 1, 2026; Form 25‑NSE will be filed with the SEC to remove the listing.
• Iterum says it does not expect to file its Form 10‑K for the fiscal year ended December 31, 2025 or make any further SEC filings due to limited cash and the ongoing winding‑up process.

Why It Matters
For investors, the filing confirms that Iterum’s shares will be removed from Nasdaq and trading liquidity will be severely reduced once suspension and delisting occur. The company also expects to stop making SEC filings, which limits public financial disclosure going forward. These steps signal that the company is in formal wind‑down proceedings under Irish law, creating uncertainty about any shareholder recovery and the timing or outcome of asset sales or other creditor processes.